{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:38:14Z","timestamp":1775151494070,"version":"3.50.1"},"reference-count":203,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1157\/13096750","type":"journal-article","created":{"date-parts":[[2007,1,15]],"date-time":"2007-01-15T10:14:45Z","timestamp":1168856085000},"page":"32-53","source":"Crossref","is-referenced-by-count":50,"title":["Recomendaciones de GESIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n enero de 2007)"],"prefix":"10.1016","volume":"25","author":[{"given":"J.","family":"L\u00f3pez Aldeguer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13096750_bib1","unstructured":"Panel on Clinical Practices for Treatment of HIV Infection convened by the U.S. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents \u2013 Oct 10, 2006. http:\/\/www.AIDSinfo.nih.gov (Acceso 10.11.2006)."},{"issue":"Suppl 2","key":"10.1157\/13096750_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2005.0311b.x","article-title":"British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005)","volume":"6","author":"Gazzard","year":"2005","journal-title":"HIV Med"},{"key":"10.1157\/13096750_bib3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1157\/13069520","article-title":"Recomendaciones de GESIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana (Octubre 2004)","volume":"22","author":"Iribarren","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13096750_bib5","first-page":"679","article-title":"Descenso brusco de la mortalidad por VIH-1\/SIDA en la Comunidad de Madrid","volume":"110","author":"Alberdi","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"10.1157\/13096750_bib6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","article-title":"Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease","volume":"351","author":"Cameron","year":"1998","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJM199610103351501","article-title":"A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team","volume":"335","author":"Hammer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib10","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","article-title":"Changing patterns of mortality across Europe in patients infected with HIV-1","volume":"352","author":"Mocroft","year":"1998","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00002030-199712000-00003","article-title":"Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA","volume":"11","author":"Mouton","year":"1997","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00002030-199902250-00015","article-title":"The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection","volume":"13","author":"Paul","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJM199705223362118","article-title":"Impact of combination therapy for HIV infection on inpatient census","volume":"336","author":"Torres","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1157\/13073149","article-title":"Recomendaciones GESIDA\/SEFH\/PNS para mejorar la adherencia al tratamiento antirretroviral en el a\u00f1o 2004","volume":"23","author":"Knobel","year":"2005","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13096750_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/infdis\/173.2.321","article-title":"Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir","volume":"173","author":"Kelleher","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00002030-200103300-00008","article-title":"Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy","volume":"15","author":"Tebas","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"key":"10.1157\/13096750_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(05)78279-9","article-title":"Effect of HAART on natural history of AIDS-related opportunistic disorders","volume":"351","author":"Sepkowitz","year":"1998","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archinte.165.10.1133","article-title":"Physician specialization and the quality of care for human immunodeficiency virus infection","volume":"165","author":"Landon","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1157\/13096750_bib22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0140-6736(96)11431-8","article-title":"Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy","volume":"349","author":"Jacobson","year":"1997","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib23","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/00002030-199814000-00013","article-title":"Opportunistic infections occurring during highly active antiretroviral treatment","volume":"12","author":"Michelet","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib24","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(97)10291-4","article-title":"Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease","volume":"351","author":"Li","year":"1998","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00002030-199818000-00001","article-title":"Diversity of the T-cell receptor BV repertoire in HIV-1-infected patients reflects the biphasic CD4+ T-cell repopulation kinetics during highly active antiretroviral therapy","volume":"12","author":"Kostense","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200101183440301","article-title":"A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04\/98","volume":"344","author":"L\u00f3pez Bernaldo de Quir\u00f3s","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002030-199904160-00001","article-title":"HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy","volume":"13","author":"Deeks","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib28","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/00002030-199911120-00009","article-title":"The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program","volume":"13","author":"Brambilla","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/clinids\/21.5.1121","article-title":"Potential clinical implications of interlaboratory variability in CD4+ T-lymphocyte counts of patients infected with human immunodeficiency virus","volume":"21","author":"Sax","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-0320(19991015)38:5<231::AID-CYTO5>3.0.CO;2-Y","article-title":"Enumeration of CD4(+) T-cells in the peripheral blood of HIV-infected patients: an interlaboratory study of the FACSCount system","volume":"38","author":"Lopez","year":"1999","journal-title":"Cytometry"},{"key":"10.1157\/13096750_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00002030-199805000-00001","article-title":"The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir","volume":"12","author":"Kempf","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib32","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/00002030-199813000-00008","article-title":"Suppression of plasma viral load below 20 copies\/ml is required to achieve a long-term response to therapy","volume":"12","author":"Raboud","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.7326\/0003-4819-135-11-200112040-00007","article-title":"Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320","volume":"135","author":"Demeter","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1157\/13096750_bib34","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/320192","article-title":"Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy","volume":"183","author":"Huang","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00002030-200403260-00008","article-title":"Long-term safety and durable antiretroviral activity of lopinavir\/ritonavir in treatment-naive patients: 4 year follow-up study","volume":"18","author":"Hicks","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib36","first-page":"96","article-title":"Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution","volume":"13","author":"Siliciano","year":"2005","journal-title":"Top HIV Med"},{"key":"10.1157\/13096750_bib37","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1086\/423388","article-title":"Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy","volume":"39","author":"Nettles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib38","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/00002030-200209270-00017","article-title":"Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy","volume":"16","author":"Greub","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.286.2.171","article-title":"Prevalence and predictive value of intermittent viremia with combination HIV therapy","volume":"286","author":"Havlir","year":"2001","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/00002030-200303280-00021","article-title":"Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies\/ ml followed for up to 4 years","volume":"17","author":"Lampe","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135965350200700404","article-title":"Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure","volume":"7","author":"Mira","year":"2002","journal-title":"Antivir Ther"},{"key":"10.1157\/13096750_bib42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1157\/13096750_bib43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nm0696-625","article-title":"HIV viral load markers in clinical practice","volume":"2","author":"Saag","year":"1996","journal-title":"Nat Med"},{"key":"10.1157\/13096750_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel","volume":"37","author":"Hirsch","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00002030-199912240-00001","article-title":"Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy","volume":"13","author":"Devereux","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/427212","article-title":"Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy","volume":"40","author":"Novak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib47","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib48","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bmj.38665.534595.55","article-title":"Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study","volume":"331","author":"Cane","year":"2005","journal-title":"BMJ"},{"key":"10.1157\/13096750_bib49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00002030-199809000-00008","article-title":"Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain","volume":"12","author":"G\u00f3mez-Cano","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00002030-200004140-00012","article-title":"Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain","volume":"14","author":"Puig","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib51","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/496982","article-title":"Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain","volume":"41","author":"De","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/431203","article-title":"Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1","volume":"41","author":"De","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib53","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/496984","article-title":"Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis","volume":"41","author":"Sax","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib54","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1086\/496988","article-title":"Resistance testing in drug-naive HIV-infected patients: is it time?","volume":"41","author":"Hecht","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM199908053410601","article-title":"Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team","volume":"341","author":"Mofenson","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002030-200002180-00008","article-title":"HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study","volume":"14","author":"Welles","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11908-002-0071-6","article-title":"Treatment of Primary HIV","volume":"4","author":"Stekler","year":"2002","journal-title":"Curr Infect Dis Rep"},{"key":"10.1157\/13096750_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1172\/JCI21540","article-title":"Acute HIV revisited: new opportunities for treatment and prevention","volume":"113","author":"Pilcher","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1157\/13096750_bib59","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1086\/420745","article-title":"Primary HIV Type 1 Infection","volume":"38","author":"Kassutto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib60","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.163.17.2097","article-title":"Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings","volume":"163","author":"Weintrob","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1157\/13096750_bib61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1157\/13069207","article-title":"Avances en el diagn\u00f3stico y tratamiento de la infecci\u00f3n aguda por el VIH-1","volume":"22","author":"Miro","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13096750_bib62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-134-1-200101020-00010","article-title":"Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network","volume":"134","author":"Daar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1157\/13096750_bib63","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1097\/00002030-200010200-00014","article-title":"Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure","volume":"14","author":"Lindback","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib64","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00002030-200403260-00001","article-title":"Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence?","volume":"18","author":"Smith","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib65","series-title":"11th Conference on Retrovirus and Opportunistic Infections","article-title":"Effect of treatment during versus after acute retroviral syndrome on HIV viral load and CD4 cell counts within 3 years of infection","author":"Voirin","year":"2004"},{"key":"10.1157\/13096750_bib66","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/500410","article-title":"Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection","volume":"42","author":"Kassutto","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib67","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0213-005X(06)73769-7","article-title":"Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003)","volume":"24","author":"Sued","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13096750_bib68","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/00002030-200212060-00011","article-title":"Virologic and immunologic values allowing safe deferral of antiretroviral therapy","volume":"16","author":"Phair","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/00002030-200105250-00006","article-title":"When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study","volume":"15","author":"Cozzi Lepri","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib70","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.286.20.2560","article-title":"HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load","volume":"286","author":"Phillips","year":"2001","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib71","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/01.aids.0000226951.49353.ed","article-title":"Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells\/microl","volume":"20","author":"Wood","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib72","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1001\/jama.286.20.2568","article-title":"Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy","volume":"286","author":"Hogg","year":"2001","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib73","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1086\/379201","article-title":"Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy","volume":"188","author":"Wood","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib74","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":"Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 \u00d7 10(9) cells\/L","volume":"139","author":"Wood","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1157\/13096750_bib75","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/377606","article-title":"When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts < 350 cells\/microL","volume":"37","author":"Kaplan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib76","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/00002030-200111230-00006","article-title":"HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy","volume":"15","author":"Sterling","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib77","series-title":"13th Conference on Retrovirus and Opportunistic Infection","article-title":"Increases in CD4 cell count to 5 years in persons with sustained virologic suppression","author":"Keruly","year":"2006"},{"key":"10.1157\/13096750_bib78","series-title":"13th Conference on Retrovirus and Opportunistic Infection","article-title":"Estimating the optimum CD4 threshold for starting HAART in ART-na\u00efve HIV-infected individuals","author":"Sterne","year":"2006"},{"key":"10.1157\/13096750_bib79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-1293.2006.00397.x","article-title":"CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells\/microL","volume":"7","author":"Moore","year":"2006","journal-title":"HIV Med"},{"issue":"RR-17","key":"10.1157\/13096750_bib80","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep"},{"key":"10.1157\/13096750_bib81","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","article-title":"Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults","volume":"15","author":"Bartlett","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib82","series-title":"XVI International AIDS Conference","article-title":"A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142","author":"Riddler","year":"2006"},{"key":"10.1157\/13096750_bib83","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1086\/422037","article-title":"Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir\/ritonavir, in antiretroviral therapy- naive patients","volume":"190","author":"King","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib84","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00126334-200404010-00003","article-title":"Clinical, virologic, and immunologic response to efavirenz or protease inhibitor based highly active antiretroviral therapy in a cohort of antiretroviral-na\u00efve patients with advanced HIV infection (EfaVIP 2 Study)","volume":"35","author":"Pulido","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib85","series-title":"10th European AIDS Conference","author":"Miro","year":"2005"},{"key":"10.1157\/13096750_bib86","series-title":"XVI International AIDS Conference","article-title":"Efavirenz-based regimens are potent in treatment-naive subjects across a wide range of pre-treatment HIV-1 RNA and CD4 cell counts: 3-year results from ACTG 5095","author":"Ribaudo","year":"2006"},{"key":"10.1157\/13096750_bib87","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMoa031772","article-title":"Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection","volume":"350","author":"Gulick","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib88","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/00002030-200305020-00007","article-title":"A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients","volume":"17","author":"Van Leeuwen","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib89","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.285.9.1155","article-title":"Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial","volume":"285","author":"Staszewski","year":"2001","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib90","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199912163412501","article-title":"Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team","volume":"341","author":"Staszewski","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib91","series-title":"10th European AIDS Conference","article-title":"Lower rate of virological suppression in naive patients initiating HAART with NRTI-sparing regimen compared to standard NRTI-containing regimen: results from Hippocampe \u2013 ANRS 121 Trial","author":"Duvivier","year":"2005"},{"key":"10.1157\/13096750_bib92","series-title":"12th Conference on Retroviruses and Opportunistic Infections","article-title":"Randomized, controlled trial of lopinavir\/ritonavir + efavirenz vs efavirenz + 2 nucleoside reverse transcriptase inhibitors following a first suppressive 3-or 4-drug regimen in advanced HIV disease","author":"Fischl","year":"2005"},{"key":"10.1157\/13096750_bib93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.qai.0000169664.15536.20","article-title":"Induction with abacavir\/lamivudine\/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir\/lamivudine\/zidovudine alone in antiretroviral-naive HIV-1-infected patients","volume":"39","author":"Markowitz","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib94","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa030265","article-title":"Comparison of four-drug regimens and pairs of sequential three- drugs regimens as inicial therapy for HIV-1 infection","volume":"349","author":"Shafer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib95","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jama.296.7.769","article-title":"Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial","volume":"296","author":"Gulick","year":"2006","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib96","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/01.aids.0000162337.58557.3d","article-title":"Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice","volume":"19","author":"Phillips","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib97","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib98","series-title":"XVI International AIDS Conference","article-title":"Efficacy and safety of tenofovir DF, emtricitabine and efavirenz compared to fixed dose zidovudine\/lamivudine and EFV through 96 weeks in antiretroviral treatment-na\u00efve patients","author":"Gallant","year":"2006"},{"key":"10.1157\/13096750_bib99","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.292.2.180","article-title":"Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial","volume":"292","author":"Saag","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib100","unstructured":"Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United Sta-tes, Oct 12, 2006. Disponible en: http:\/\/www.aidsinfo.nih.gov\/guidelines\/ (Acceso: 10.11.2006)."},{"key":"10.1157\/13096750_bib101","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00002030-200501280-00017","article-title":"Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine","volume":"19","author":"Le\u00f3n","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib102","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1086\/432879","article-title":"Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies","volume":"41","author":"Negredo","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(04)16591-4","article-title":"Pancreatic toxic effects associated with the co-administration of didanosine and tenofovir in HIV-infected adults","volume":"364","author":"Martinez","year":"2004","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib104","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/135965350501000117","article-title":"Early virological failure with a combination of tenofovir, didanosine and efavirenz","volume":"10","author":"Podzamczer","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1157\/13096750_bib105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/01.aids.0000166092.39317.42","article-title":"MA. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir","volume":"19","author":"P\u00e9rez El\u00edas","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib106","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00002030-200004140-00006","article-title":"Efficacy, safety, and adherence with a twice-daily combination lamivudine\/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection","volume":"14","author":"Eron","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib107","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/424009","article-title":"Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults","volume":"39","author":"DeJes\u00fas","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.qai.0000242449.67155.1a","article-title":"A Once-Daily Lopinavir\/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen","volume":"43","author":"Johnson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/135965350300800411","article-title":"Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients","volume":"8","author":"Maggiolo","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1157\/13096750_bib111","series-title":"12th Conference on Retrovirus and Opportunistic Infections","article-title":"A randomized comparison between abacavir and stavudine, both combined with lamivudine\/efavirenz, in antiretroviral-naive patients. Final 96-week results of the ABCD Study","author":"Podzamczer","year":"2005"},{"key":"10.1157\/13096750_bib112","series-title":"12th Conference on Retrovirus and Opportunistic Infections","article-title":"A 48-week, randomized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART","author":"Moyle","year":"2005"},{"key":"10.1157\/13096750_bib113","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1097\/00002030-200309260-00005","article-title":"Low efficacy and high frequency of adverse events in a randomized trial of the triple NRTI regimen abacavir, stavudine and didanosine","volume":"17","author":"Gerstoft","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib114","series-title":"XIV International AIDS Conference","article-title":"Abacavir\/Lamivudine (ABC\/3TC) in combination with Efavirenz (NNRTI), Amprenavir\/Ritonavir (PI) or Stavudine (NRTI): ESS40001 (CLASS) preliminary 48 week results","author":"Bartlett","year":"2002"},{"key":"10.1157\/13096750_bib115","series-title":"43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Early Non-Response to Tenofovir DF (TDF) + Abacavir (ABC) and Lamivudine (3TC) in a Randomized Trial Compared to Efavirenz (EFV) + ABC and 3TC: ESS30009 Unplanned Interim Analysis","author":"Gallant","year":"2003"},{"key":"10.1157\/13096750_bib116","unstructured":"Gilead. High rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI regimen containing didanosine, lamivudine, and tenofovir. Gilead Sciences, Inc., October 14, 2003."},{"key":"10.1157\/13096750_bib117","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0213-005X(01)72652-3","volume":"19","author":"Iribarren","year":"2001","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13096750_bib118","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"Van Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib119","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of secuential three-drug regimens as inicial therapy for HIV-1 infecti\u00f3n","volume":"349","author":"Robbins","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib120","unstructured":"Montaner JSG, Schutz M, Schwartz R, Jayaweera D, Burnside AF, Walmsley S, et al. Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin aapsule\/ritonavir in antiretroviral-naive, HIV-infected patients. eJIAS http:\/\/www.medscape.com\/viewarticle\/528558 (acceso 10.11.06)."},{"key":"10.1157\/13096750_bib121","series-title":"10th European AIDS Conference","article-title":"Seven year follow-up of a lopinavir\/ritonavir-based regimen in antiretroviral-na\u00efve subjects","author":"Murphy","year":"2005"},{"key":"10.1157\/13096750_bib122","series-title":"3rd IAS Conference on HIV Pathogenesis and Treatment","article-title":"Significantly reduced food effect and pharmacokinetic variability with a novel lopinavir\/ ritonavir tablet formulation","author":"Awni","year":"2005"},{"key":"10.1157\/13096750_bib123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00002030-199901140-00002","article-title":"Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial","volume":"13","author":"Kirk","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib124","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200401010-00003","article-title":"The NEAT Study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy na\u00efve HIV-1-infected patients","volume":"35","author":"Rodr\u00edguez-French","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib125","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.aids.0000131332.30548.92","article-title":"SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir \/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients","volume":"18","author":"Gathe","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib126","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200301010-00004","article-title":"Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects","volume":"32","author":"Sanne","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib127","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/00002030-200312050-00007","article-title":"Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results","volume":"17","author":"Murphy","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib128","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00126334-200406010-00005","article-title":"Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir","volume":"36","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib129","series-title":"13th Conference on Retrovirus and Opportunistic Infection","article-title":"Efficacy and safety of atazanavir-based therapy in antiretroviral na\u00efve HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089","author":"Malan","year":"2006"},{"key":"10.1157\/13096750_bib130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib131","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","article-title":"Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions","volume":"131","author":"Lucas","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1157\/13096750_bib132","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study","volume":"353","author":"Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib133","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/00002030-200409240-00005","article-title":"The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection","volume":"18","author":"Klein","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib134","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1157\/13085280","article-title":"Tratamiento antirretroviral de la infecci\u00f3n por el virus de la inmunodeficiencia humana: duraci\u00f3n y motivos de cambio del primer esquema terap\u00e9utico en 518 pacientes","volume":"126","author":"Gratacos","year":"2006","journal-title":"Med Clin (Barc)"},{"issue":"Suppl 1","key":"10.1157\/13096750_bib135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qai.0000137005.63376.6e","article-title":"Resistance issues with new nucleoside\/nucleotide backbone options","volume":"d37","author":"Wainberg","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib136","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"issue":"Suppl A","key":"10.1157\/13096750_bib137","first-page":"271","article-title":"Adherence: a necessity for successful HIV combination therapy","volume":"13","author":"Chesney","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib138","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/00002030-199906180-00014","article-title":"The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response","volume":"13","author":"Haubrich","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib139","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMoa013552","article-title":"Antiretroviral-drug resistance among patients recently infected with HIV","volume":"347","author":"Little","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib140","series-title":"2nd IAS Conference on HIV Pathogenesis and Treatment","article-title":"Geographic variation in prevalence of mutations associated with resistance to antiretroviral drugs among drug-naive persons newly diagnosed with HIV in ten US cities, 1997-2001","author":"Bennett","year":"2003"},{"key":"10.1157\/13096750_bib141","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1097\/00002030-200112070-00005","article-title":"Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals","volume":"15","author":"Phillips","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib142","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00042560-200110010-00001","article-title":"Transient relapses (\u201cblips\u201d) of plasma HIV RNA levels during HAART are associated with drug resistance","volume":"28","author":"Cohen","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib143","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1086\/496985","article-title":"Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor- based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis","volume":"41","author":"Sungkanuparph","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib144","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1097\/00002030-200411190-00024","article-title":"A 7-year longitudinal analysis of IL-2 in patients treated with highly active antiretroviral therapy","volume":"18","author":"Lichtenstein","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib145","series-title":"10th European AIDS Conference","article-title":"Interleukin- 2 as treatment for immunological discordant patietns with low CD4 cell counts alter at least one year of HAART-Gesidad33\/03","author":"L\u00f3pez","year":"2005"},{"key":"10.1157\/13096750_bib146","series-title":"13th Conference on Retrovirus and Opportunistic Infection","article-title":"Characteristics and outcome of AIDS-related non-Hodgkin's lymphoma in patients treated with HAART","author":"Berenguer","year":"2006"},{"key":"10.1157\/13096750_bib147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS","volume":"14","author":"Baxter","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib148","series-title":"11th Conference on Retroviruses and Opportunistic Infections","article-title":"Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF","author":"Jemsek","year":"2004"},{"key":"10.1157\/13096750_bib149","series-title":"11th Conference on Retroviruses and Opportunistic Infections","article-title":"Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: The Tonus study","author":"Landman","year":"2004"},{"key":"10.1157\/13096750_bib150","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00002030-200304110-00007","article-title":"Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs","volume":"17","author":"KATVenstein","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib151","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/nar\/27.1.348","article-title":"Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database","volume":"27","author":"Shafer","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"10.1157\/13096750_bib152","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002030-200201040-00004","article-title":"Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen","volume":"16","author":"Le Moing","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib153","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/00002030-200007070-00005","article-title":"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study","volume":"14","author":"Durant","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib154","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00002030-199811000-00002","article-title":"The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy","volume":"12","author":"Hoetelmans","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib155","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nm0796-760","article-title":"Ordered accumulation of mutations in HIV protease confers resistance to ritonavir","volume":"2","author":"Molla","year":"1996","journal-title":"Nat Med"},{"key":"10.1157\/13096750_bib156","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00002030-200103300-00010","article-title":"Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors","volume":"15","author":"Kemper","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib157","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1086\/386291","article-title":"Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment- naive HIV-1-infected patients receiving ATV-containing regimens","volume":"189","author":"Colonno","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib158","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1086\/315782","article-title":"Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy","volume":"182","author":"Condra","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib159","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/01.aids.0000189569.10471.b4","article-title":"Long-term antiretroviral efficacy and safety of lopinavir\/ritonavir in HAART-experienced subjects: 4 year follow-up study","volume":"19","author":"Bongiovanni","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib160","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1310\/H5JN-MFG3-G35K-QX9J","article-title":"Salvage treatment with lopinavir\/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families","volume":"3","author":"De Mendoza","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13096750_bib161","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/380799","article-title":"Once-daily versus twice-daily lopinavir\/ritonavir in antiretroviral-na\u00efve HIV-positive patients: a 48-week randomized clinical trial","volume":"189","author":"Eron","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib162","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00002030-200101260-00009","article-title":"The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study","volume":"15","author":"Mocroft","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib163","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/00002030-200108170-00019","article-title":"Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy","volume":"15","author":"Walmsley","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib164","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dki170","article-title":"Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol","volume":"56","author":"Latham","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1157\/13096750_bib165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.aids.0000196174.80798.5b","article-title":"Once-daily directly observed therapy lopinavir\/ ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study","volume":"20","author":"Elzi","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib166","series-title":"13th Conference on Retroviruses and Opportunistics Infections","article-title":"Improved virologic outcomes and less HIV resistance for HAART-experienced substance users receiving modified directly observed therapy: results from a randomized controlled trial","author":"Mitty","year":"2006"},{"key":"10.1157\/13096750_bib167","series-title":"13th Conference on Retroviruses and Opportunistics Infections","article-title":"Enhanced survival associated with use of HIV susceptibility testing among HAART-experienced patients in the HIV Outpatient Study (HOPS)","author":"Palella","year":"2006"},{"key":"10.1157\/13096750_bib168","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0924-8579(02)00250-9","article-title":"Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors","volume":"20","author":"Barreiro","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1157\/13096750_bib169","series-title":"13th Conference on Retroviruses and Opportunistics Infections","article-title":"Improved ART exposure with therapeutic drug monitoring","author":"Best","year":"2006"},{"key":"10.1157\/13096750_bib170","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/01.aids.0000181009.77632.36","article-title":"The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals","volume":"19","author":"Winston","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib171","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/00002030-200009080-00009","article-title":"Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples","volume":"14","author":"Larder","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib172","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib173","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/01.aids.0000171408.38490.01","article-title":"TMC114\/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial","volume":"19","author":"Arasteh","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib174","series-title":"XVI International AIDS Conference","article-title":"TMC114 provides durable viral load suppression in treatment- experienced patients: POWER 1 and 2 combined week 48 analysis","author":"Lazzarin","year":"2006"},{"key":"10.1157\/13096750_bib175","series-title":"44th Annual meeting of the Infectious Disease Society of America","article-title":"Efficacy and safety results of darunavir\/r in treatment-experienced patients: POWER 3","author":"Saag","year":"2006"},{"key":"10.1157\/13096750_bib176","series-title":"XV International HIV Drug Resistance Workshop","article-title":"Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3","author":"De Meyer","year":"2006"},{"key":"10.1157\/13096750_bib177","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib178","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib179","series-title":"2nd IAS Conference on HIV Pathogenesis and Treatment","article-title":"Enfuvirtide TORO studies: 48 week results confirm 24 week findings","author":"Katlama","year":"2003"},{"key":"10.1157\/13096750_bib180","series-title":"43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Durability of Response of Enfuvirtide through 48 Weeks in the TORO Trials","author":"Trottieri","year":"2003"},{"key":"10.1157\/13096750_bib181","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1310\/0XH7-F2V2-1K0R-NU2W","article-title":"Prognostic staging of extensively pretreated patients with advanced HIV-1 disease","volume":"6","author":"Montaner","year":"2005","journal-title":"HIV Clin Trials"},{"key":"10.1157\/13096750_bib182","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/500206","article-title":"Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials","volume":"42","author":"Raffi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13096750_bib183","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/01.ftd.0000177663.89103.58","article-title":"No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach","volume":"27","author":"Dailly","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1157\/13096750_bib184","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1128\/AAC.48.11.4256-4262.2004","article-title":"Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults","volume":"48","author":"Ribera","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13096750_bib185","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00002030-200203290-00018","article-title":"Drug interaction between amprenavir and lopinavir\/ritonavir in salvage therapy","volume":"16","author":"Khanlou","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib186","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00002030-200501280-00006","article-title":"Combining fosamprenavir with lopinavir\/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results","volume":"19","author":"Kashuba","year":"2005","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib187","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.aids.0000226953.56976.ad","article-title":"Atazanavir and lopinavir\/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen","volume":"20","author":"Ribera","year":"2006","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib188","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/315334","article-title":"Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection","volume":"181","author":"Deeks","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1157\/13096750_bib189","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-133-6-200009190-00007","article-title":"Clinical outcome of patients with HIV < -1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy","volume":"133","author":"Grabar","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1157\/13096750_bib190","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00002030-200201250-00009","article-title":"Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia","volume":"16","author":"Deeks","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib191","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00002030-200101050-00017","article-title":"Reassessing the goal of antiretroviral therapy in the heavily pre-treated HIV-infected patient","volume":"15","author":"Deeks","year":"2001","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib192","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1258\/0956462011923093","article-title":"Salvage treatment in HIV disease","volume":"12","author":"Youle","year":"2001","journal-title":"Int J STD AIDS"},{"key":"10.1157\/13096750_bib193","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11904-006-0022-1","article-title":"Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature","volume":"3","author":"Anderson","year":"2006","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"Suppl 2","key":"10.1157\/13096750_bib194","first-page":"48","article-title":"Simplificaci\u00f3n del tratamiento antiretroviral","volume":"20","author":"Ribera","year":"2002","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1157\/13096750_bib195","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team","volume":"339","author":"Havlir","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib196","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(98)06193-5","article-title":"Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study","volume":"352","author":"Reijers","year":"1998","journal-title":"Lancet"},{"key":"10.1157\/13096750_bib197","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00002030-200203080-00007","article-title":"Final analysis of the Trilege induction-maintenance trial: results at 18 months","volume":"16","author":"Flandre","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13096750_bib198","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJM199810293391810","article-title":"Therapeutic strategies for HIV infection-time to think hard","volume":"339","author":"Cooper","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib199","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.qai.0000180077.59159.f4","article-title":"Lopinavir\/ ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)","volume":"40","author":"Arribas","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13096750_bib200","series-title":"XVI International AIDS Conference","article-title":"Lopinavir\/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: Forty eight week results of a randomized, controlled, open label, clinical trial (OK04 Study)","author":"Arribas","year":"2006"},{"key":"10.1157\/13096750_bib201","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.296.7.806","article-title":"Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression","volume":"296","author":"Swindells","year":"2006","journal-title":"JAMA"},{"key":"10.1157\/13096750_bib202","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Mart\u00ednez","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13096750_bib203","series-title":"10th European AIDS Conference","article-title":"Efficacy and safety of atazanavir based HAART in patients switching from a stable boosted\/unboosted protease inhibitor treatment: the SWAN Study","author":"Gatell","year":"2005"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X07742258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X07742258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T10:25:39Z","timestamp":1683714339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X07742258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":203,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0213005X07742258"],"URL":"https:\/\/doi.org\/10.1157\/13096750","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}